Trading Systems Reacting to (CRMD) Volatility
This article analyzes Cormedix Inc. (CRMD) showing strong near and mid-term sentiment but a weak long-term outlook. It identifies a mid-channel oscillation pattern and highlights an exceptional 124.5:1 risk-reward setup. The analysis also provides three distinct AI-generated trading strategies for various risk profiles.
CorMedix (NasdaqGM:CRMD) Stock Price
This article provides a detailed overview of CorMedix Inc. (CRMD) stock performance, valuation, and investment narratives from Simply Wall St. It highlights CorMedix's current stock price, fair value estimates, recent analyst updates, and key investment theses revolving around its product DefenCath and recent acquisition. The article also outlines risk considerations, financial details, and upcoming pipeline events.
CorMedix Inc. (CRMD) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for CorMedix Inc. (CRMD) from NASDAQ. It displays the current stock price, its daily change, and options to view historical data over various periods. The article also mentions the absence of current analyst ratings and earnings information for CorMedix Inc.
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast?
The article discusses the 2025 revenue forecast for CorMedix Inc. (CRMD) stock. Analysts predict a range of revenues, with an average estimate of $133.05 million. This forecast suggests significant growth potential for the company.
CRMD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of CorMedix Inc (CRMD), focusing on its revenue breakdown, profitability margins, and competitive positioning. CRMD boasts a gross margin of 83.43%, an operating margin of 45.97%, and a net margin of 10.90%, alongside a Return on Equity (ROE) of 66.56%. The article also compares CRMD's market capitalization of $536.75M and its gross margin against competitors CTNM and CMPS, for which gross margin data is N/A.
CorMedix soars on increased Q2 sales guidance
CorMedix (CRMD) stock rose significantly after the company provided increased sales guidance for the second quarter. The company stated it now expects net sales of Defencath to be between $5.6 million and $6 million, up from previous estimates of $4.5 million to $5.0 million. This positive outlook is attributed to strong demand and operational performance.
Vanguard disaggregates holdings; reports 0% in CorMedix (CRMD)
Vanguard has filed an amended Schedule 13G stating it now holds 0 shares and 0% ownership of CorMedix Inc. common stock. This change is due to an internal realignment where certain Vanguard subsidiaries will report their holdings separately, in accordance with SEC Release No. 34-39538. The filing indicates an administrative reorganization rather than a trading decision affecting CorMedix's capital structure.
Do Options Traders Know Something About CorMedix Stock We Don't?
Investors should examine CorMedix Inc. (CRMD) due to unusual activity in its options market, specifically the May 15, 2026 $3 Call, which shows high implied volatility. Despite this, CorMedix holds a Zacks Rank #4 (Sell), with analysts revising earnings estimates downward. This discrepancy suggests potential trading opportunities for options traders, possibly involving selling premium.
How Cormedix Inc. (CRMD) Affects Rotational Strategy Timing
This article analyzes Cormedix Inc. (CRMD) using AI models to determine its effect on rotational strategy timing. It highlights weak sentiment across all horizons, supporting a short bias, and provides three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal data and risk-reward setups.
CRMD: Investor Day Will Clarify Lower Guidance And Highlight Perceived Upside
CorMedix's upcoming Investor Day is anticipated to provide further details on the commercialization and long-term revenue potential of DefenCath and REZZAYO, following recent analyst price target reductions. While analysts have lowered guidance for DefenCath revenue, many still see upside potential if the company executes its commercial plan, supported by the newly introduced multi-year revenue guidance. The company has also reiterated its 2026 net revenue guidance of US$300-320 million and authorized a share repurchase plan.
Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines?
CorMedix (CRMD) has experienced significant share price declines recently, with a 47.6% drop year to date. Despite this, Simply Wall St's analysis, including a Discounted Cash Flow (DCF) model and Price-to-Earnings (P/E) ratio comparison, suggests the stock is substantially undervalued. The DCF model indicates a 93.0% undervaluation, and its current P/E of 3.11x is well below the industry average, presenting a potential opportunity for investors.
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains
CorMedix (CRMD) has experienced recent share price weakness, with a 10.9% decline over the past month and a 42.8% decline over the past three months, despite a 91.2% gain over the past three years. The stock closed at US$6.54, which is significantly below the analyst-assigned fair value of $14.57 per share, suggesting it is 55.1% undervalued. This valuation is driven by expectations of robust top-line expansion, higher margins, and a lower future earnings multiple, though risks like integration challenges and pricing pressures could impact future growth.
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains
CorMedix (CRMD) is currently assessed as 55.1% undervalued by analysts, with a fair value target of $14.57 per share compared to its last close of $6.54. This valuation is driven by expectations of robust top-line expansion and higher margins, despite recent share price declines. The company's pipeline, including DefenCath's Phase III trials and potential REZZAYO label expansion, targets growing patient populations, suggesting long-term revenue growth potential.
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD)
This article provides a detailed overview of CORMEDIX INC (CRMD) stock, including its current price, performance, and key statistics. It also features technical and fundamental analyses, earnings reports, analyst forecasts, financial highlights, and ownership details. CorMedix Inc. is a pharmaceutical and medical device company focused on developing and commercializing therapeutic products, with its lead product DefenCath aimed at reducing catheter-related bloodstream infections.
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit Swing - What's Changed
CorMedix (CRMD) experienced a 9.4% drop in stock price despite reaffirming its 2026 net revenue guidance of US$300 million to US$320 million and reporting a significant swing to profit in 2025. The company's focus remains on integrating DefenCath sales with evolving Medicare rules and advancing late-stage trials for REZZAYO. Investors are now evaluating how future reimbursement shifts and clinical trial outcomes will impact the company's investment narrative and risk profile.
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit Swing - What's Changed
CorMedix (CRMD) reported past fourth-quarter 2025 revenue of US$128.62 million and a net income of US$14.02 million, with full-year revenue reaching US$311.71 million and net income swinging to US$163.06 million from a prior loss. The company reiterated its 2026 net revenue guidance of US$300 million to US$320 million, signaling management's focus on current product gains and upcoming revenue sources. While the financial results were strong, investors are urged to consider how future reimbursement shifts and the performance of pipeline assets like REZZAYO could impact the company's long-term outlook.
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit Swing - What's Changed
CorMedix Inc. (CRMD) experienced a 9.4% stock drop despite reporting strong fourth-quarter and full-year 2025 results, with revenue reaching US$128.62 million and a significant profit swing to US$163.06 million for the year. The company reaffirmed its 2026 net revenue guidance of US$300 million to US$320 million, signaling management's focus on integrating DefenCath sales and advancing late-stage pipeline assets like REZZAYO. Investors are now focused on how future reimbursement shifts and REZZAYO data will impact the company's financial outlook and current investment narrative.
CorMedix (Nasdaq: CRMD) swings to 2025 profit as revenue surges
CorMedix Inc. reported a significant financial turnaround in 2025, swinging to a net profit of $163.1 million, or $2.04 per diluted share, from a $17.9 million loss in 2024. This growth was driven by strong revenues from DefenCath and the acquisition of the Melinta portfolio, contributing to total revenues of $311.7 million, with a pro forma total of $401.3 million including a full year of Melinta sales. The company also reported strong liquidity with $148.5 million in cash and short-term investments by year-end 2025, and reiterated its 2026 revenue and adjusted EBITDA guidance.
Leerink cuts CorMedix stock price target on expense adjustments
Leerink Partners has lowered its price target on CorMedix Inc. (NASDAQ:CRMD) to $13 from $15, while maintaining an Outperform rating, due to adjusted operating expense projections. This follows the company's Q4 2025 results and management discussion, with 2026 expected to be a transition year due to DefenCath reimbursement changes. Despite a recent EPS miss, the firm sees potential catalysts and considers the stock undervalued, with Truist Securities also reiterating a Buy rating.
CorMedix (NASDAQ: CRMD) reaffirms DefenCath 2027 sales outlook
CorMedix (NASDAQ: CRMD) has reaffirmed its 2027 DefenCath sales guidance of $100–$140 million, correcting a narrower range inadvertently mentioned on a recent earnings call. The company also provided a broader growth outlook, including 2026 revenue guidance of $300–$320 million and adjusted EBITDA of $100–$125 million, supported by its diversified anti-infective portfolio. CorMedix highlighted ongoing Phase 3 trials for DefenCath in total parenteral nutrition and REZZAYO for fungal prophylaxis, indicating significant future market expansion opportunities and a strong balance sheet with $149 million in cash and short-term investments.
CorMedix (NasdaqGM:CRMD) Stock Forecast & Analyst Predictions
CorMedix (NasdaqGM:CRMD) is forecast to grow earnings by 6.8% and revenue by 11.3% annually, although EPS is expected to decline by 2.5%. The company's DefenCath product, the only FDA-approved antimicrobial CLS in the U.S., provides a strong regulatory moat. CRMD's investment thesis highlights its current stock price nearing its bear case, suggesting potential upside from pipeline events like the REZZAYO prophylaxis Phase III trial and DefenCath TPN.
CorMedix Inc. (NASDAQ:CRMD) Q4 2025 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD) held its Q4 and full-year 2025 earnings call, discussing a "transformational year" marked by the acquisition of Melinta Therapeutics and strong DEFENCATH sales, despite missing EPS expectations. The company provided 2026 and 2027 guidance for DEFENCATH amidst changes in reimbursement strategy and affirmed overall financial guidance for 2026. CorMedix also highlighted progress on its pipeline, including RIZEAO for prophylaxis of fungal infections and DEFENCATH for CLABSI prevention, with key data readouts anticipated soon.
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting $128.6 million in net revenue for Q4 2025 and $401.3 million in pro forma revenue for the full year. The company saw a net income of $14.0 million in Q4 and $163.0 million for the full year, significantly driven by DefenCath sales and the acquisition of Melinta. CorMedix reiterated its 2026 revenue guidance and highlighted progress in its clinical programs and a share repurchase program.
CorMedix (CRMD) reports higher Q4 2025 profit on strong revenue growth
CorMedix Inc. (NASDAQ: CRMD) reported a significant increase in Q4 2025 revenues, reaching $128.6 million, primarily due to strong utilization of DefenCath. The company posted a net income of $14.02 million for the quarter and reaffirmed its 2026 revenue guidance between $300 million and $320 million, with adjusted EBITDA forecasted at $100-125 million. CorMedix also announced a share repurchase program of up to $75 million.
Why Did CRMD Stock Tumble Over 11% Today?
CorMedix (CRMD) stock tumbled over 11% despite reporting a 312% year-on-year jump in Q4 revenue to $128.6 million, exceeding analyst estimates. The revenue growth was driven by DefenCath sales and the Melinta acquisition. However, the company's earnings per share of $0.16 significantly missed the estimated $0.82, and operating expenses rose 181% due to the Melinta acquisition, leading to the stock's decline.
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. announced strong financial results for Q4 and full-year 2025, with Q4 net revenue of $128.6 million and full-year pro forma net revenue of $401.3 million, driven significantly by DefenCath sales and the acquisition of Melinta. The company reported a net income of $14.0 million and adjusted EBITDA of $77.2 million for the fourth quarter, and reiterated its 2026 guidance. CorMedix also highlighted ongoing clinical trials for REZZAYO and DefenCath, and announced a $75 million share repurchase program.
CorMedix: Q4 Earnings Snapshot
CorMedix Inc. (CRMD) reported a strong fourth quarter with a profit of $14 million, or 16 cents per share, adjusted to 61 cents per share. The company's revenue for the quarter was $128.6 million. For the full year, CorMedix posted a profit of $163.1 million, or $2.04 per share, on revenues of $311.7 million.
CORMEDIX ($CRMD) Releases Q4 2025 Earnings
CORMEDIX ($CRMD) reported its Q4 2025 earnings, missing both earnings per share estimates ($0.61 vs. $0.83) and revenue estimates ($128.62 million vs. $129.56 million). The report also details significant insider selling activity, with 14 sales and 1 purchase over the last six months, and outlines hedge fund activity showing both increased and decreased positions. Despite these mixed financial results and insider selling, Wall Street analysts have maintained exclusively "Buy" or "Outperform" ratings, with a median price target of $14.0.
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
CorMedix Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, showing significant growth in revenue and net income, driven by DefenCath sales and the acquisition of Melinta. The company reported net revenue of $128.6 million for Q4 2025 and $311.7 million for the full year, with a net income of $163.0 million for 2025. CorMedix also provided a positive outlook for 2026, including a share repurchase program, upcoming clinical data, and projected net revenue between $300 and $320 million.
CorMedix: Q4 Earnings Snapshot
CorMedix Inc. (CRMD) reported a profit of $14 million in its fourth quarter, translating to 16 cents per share, or 61 cents per share when adjusted for pretax expenses. The pharmaceutical and medical device company generated $128.6 million in revenue for the quarter. For the full year, CorMedix posted a profit of $163.1 million, or $2.04 per share, on revenue of $311.7 million.
Dialysis drug maker posts $163M profit, plans $75M buyback
CorMedix (Nasdaq: CRMD) reported strong financial results for Q4 and full-year 2025, with a net income of $163.0 million for the year and $128.6 million in Q4 net revenue. The company also announced a $75 million share repurchase program and reiterated its 2026 revenue guidance, showcasing its focus on driving business growth and shareholder value. Despite the positive financial performance, the stock experienced an 11.52% decline on the day the news was published, signaling a negative market reaction, possibly due to increased operating expenses or existing market volatility patterns.
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting $128.6 million in net revenue for Q4 2025 and $401.3 million pro forma net revenue for the full year. The company achieved a net income of $14.0 million in Q4 2025 and reiterated its 2026 guidance, expecting net revenue between $300 and $320 million. CorMedix also highlighted ongoing Phase 3 clinical trials for REZZAYO® and DefenCath, with key data expected in Q2 2026.
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
CorMedix Inc. (Nasdaq: CRMD) announced it will report its Q4 and full-year 2025 financial results and host a corporate update conference call on March 5, 2026, before market open. The biopharmaceutical company focuses on developing and commercializing therapeutic products for life-threatening diseases, including DefenCath and a portfolio of anti-infective products acquired from Melinta Therapeutics LLC. Upcoming milestones include topline results for a Phase III study of REZZAYO in Q2 2026.
CorMedix Inc. to Report Fourth Quarter and Full Year 2025
CorMedix Inc. (Nasdaq: CRMD) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026. The biopharmaceutical company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix is focused on developing and commercializing therapeutic products for life-threatening diseases, including DefenCath and a portfolio of anti-infective products acquired from Melinta Therapeutics.
CRMD Earnings History & Surprises | EPS & Revenue Results | CORMEDIX INC (NASDAQ:CRMD)
This article provides a detailed historical overview of CORMEDIX INC's (NASDAQ: CRMD) earnings performance, including past quarterly EPS and revenue results, analyst estimates, and surprise percentages. It also outlines upcoming earnings dates and offers analysis on the company's consistent beat rate for both EPS and revenue over the last four quarters. Investors can find data on growth trends, acceleration, and frequently asked questions regarding CRMD's earnings.
Responsive Playbooks and the CRMD Inflection
This article provides an AI-driven analysis of Cormedix Inc. (NASDAQ: CRMD), highlighting strong near-term sentiment that contrasts with persistent mid and long-term weakness. It offers detailed institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also provides key support and resistance levels for CRMD based on AI-generated signals.
Biotech CorMedix sets March 5 call on 2025 results, corporate update
CorMedix (CRMD) will report its Q4 and full-year 2025 financial results on March 5, 2026, before market open, followed by a corporate update conference call at 8:30 AM ET. The announcement details how investors can join the call via domestic or international dial-in numbers or webcast. The article also provides a market reality check, historical context of recent company events, and regulatory information, including an active S-3 Shelf Registration.
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
CorMedix Inc. (Nasdaq: CRMD) announced it will report its financial results for the fourth quarter and full year 2025 before the market opens on Thursday, March 5, 2026. The company will also host a corporate update conference call at 8:30 AM ET on the same day. CorMedix is a biopharmaceutical company focused on therapeutic products for life-threatening diseases, commercializing DefenCath and a portfolio of anti-infective products acquired from Melinta Therapeutics LLC.
CRMD Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Cormedix (CRMD), including its income statement, balance sheet, cash flow statement, and key financial ratios. It highlights that while Cormedix has a strong balance sheet and high liquidity, it currently faces profitability challenges, negative free cash flow, and a low Piotroski F-Score. The company's financial health is rated as moderate, with concerns about its ability to cover interest payments.
CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention
CorMedix (NasdaqGM:CRMD) is acquiring Melinta Therapeutics, adding seven approved therapies and expanding its presence in hospital and acute care settings with a broader anti-infective offering. This acquisition shifts CorMedix from a single-product focus to a multi-asset commercial platform, potentially changing its risk profile and revenue sources. Despite recent stock decline, the company trades significantly below analyst target prices and estimated fair value, suggesting a wide valuation gap.
Is CorMedix (CRMD) Pricing Reflect Recent Share Weakness Or Future Growth Potential
This article analyzes CorMedix (CRMD) stock pricing, concluding it is undervalued based on two valuation methods. Despite recent share price weakness, a Discounted Cash Flow (DCF) analysis suggests a 92.0% undervaluation, and its P/E ratio is significantly lower than industry averages and its calculated "Fair Ratio." The article encourages investors to explore these valuations further and consider their own narratives for the company.
Evaluating CorMedix (CRMD) Valuation As Melinta Acquisition And DefenCath Outlook Refocus Investor Attention
CorMedix (CRMD) has captured investor attention due to its recent Melinta Therapeutics acquisition and upcoming DefenCath outlook. With CRMD trading at US$7.07, analysts suggest it is undervalued with a fair value of $14.86, primarily driven by the Melinta acquisition which is expected to diversify revenue and create significant synergies. However, investors are advised to weigh these opportunities against integration risks and lower DefenCath guidance.
Evaluating CorMedix (CRMD) Valuation As Melinta Acquisition And DefenCath Outlook Refocus Investor Attention
CorMedix (CRMD) stock has been re-evaluated following mixed short-term performance, with analysts suggesting it is undervalued at $7.07 against a fair value of $14.86. The recent acquisition of Melinta Therapeutics is expected to diversify and stabilize CorMedix's revenue, adding $125-$135 million in 2025 B.
CorMedix Inc (CRMD) News, Articles, Events & Latest Updates
This article provides a compilation of recent news, articles, and financial updates concerning CorMedix Inc (CRMD). It covers analyst ratings, earnings reports, stock performance analysis, and insights into the company's strategic shift towards becoming a multi-product pharmaceutical company, particularly with the performance of DefenCath and the acquisition of Melinta products.
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
CorMedix (CRMD) is set to report fourth-quarter and full-year 2025 earnings, with investors focused on DefenCath sales and the recent Melinta acquisition. Despite a strong prior earnings beat history and a positive Earnings ESP, the stock faces competitive pressures from larger players and a conservative 2026 financial outlook, dampening investor sentiment. The article suggests investors consider reducing exposure or selling CRMD due to near-term uncertainty and declining earnings estimates.
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
CorMedix (CRMD) is set to release its Q4 and full-year 2025 earnings, with investors focusing on the sales performance of its lead product, DefenCath. Despite a history of beating earnings estimates, the stock is currently rated as a Zacks Rank #5 (Strong Sell) due to competitive pressures and a conservative 2026 financial outlook. Analysts are cautious about CRMD's long-term growth given its reliance on DefenCath and the muted guidance.
A Pivotal Spring Agenda for CorMedix Investors
CorMedix is entering a crucial period this spring, marked by investor conferences, the release of Q4 earnings, and significant clinical readouts. The company will participate in several healthcare conferences in March and has authorized a new $75 million share repurchase program. Key clinical trial results for REZZAYO (Phase III "ReSPECT" trial) and development efforts for DefenCath are also anticipated in 2026, which could significantly impact the company's commercial potential.
A Pivotal Spring Agenda for CorMedix Investors
CorMedix is entering a critical period with several key events scheduled for the spring of 2026, including investor conferences in March, the release of Q4 earnings, and a new $75 million share repurchase program. Additionally, significant clinical data readouts are anticipated in Q2 2026 for its drug REZZAYO from the Phase III "ReSPECT" trial, and further development for DefenCath. These activities are expected to significantly influence the company's near-term trajectory and investor perception.
Understanding the Setup: (CRMD) and Scalable Risk
This article from Stock Traders Daily analyzes Cormedix Inc. (NASDAQ: CRMD), highlighting weak near and mid-term sentiment, and a neutral long-term outlook. It identifies elevated downside risk due to a lack of additional long-term support signals. The report also provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles.
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
CorMedix (CRMD) shares have dropped 27% over the past three months due to a cautious 2026 financial outlook, primarily for its lead product DefenCath. Despite initial strong uptake for DefenCath and the acquisition of Melinta Therapeutics for diversification, concerns about slower adoption and increased competition from larger pharmaceutical companies have impacted investor sentiment. The article suggests that due to recent price declines, conservative guidance, and downward earnings revisions, investors might consider reducing their positions or exiting the stock.
